CD274 and non-small cell lung carcinoma: We hypothesize that these radiomic features can enhance and complement the standard CT evaluations and clinical characteristics, improving our prior clinical model’s predictions for response to pembrolizumab in a high PD-L1 NSCLC patient cohort.